Cytochrome P450 Induction

Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad

Volumn , Issue , 2010, Pages 265-314

  LeCluyse, Edward L ^a   Sinz, Michael W ^b   Hewitt, Nicola ^c   Ferguson, Stephen S ^a   Sahi, Jasminder ^a  

^a CellzDirect Life Technologies   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c KaLy Cell   (France)

Author keywords

"cross talk" between receptors phase I and phase II drug metabolizing enzymes and drug transporters; Cytochrome P450 induction; Methodologies and application in drug drug interaction elimination or prediction

Indexed keywords

EID: 84884466578     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470538951.ch8     Document Type: Chapter

References (116)

1. Agarwal S, Holton KL, Lanza R. Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells 2008; 26: 1117-1127.
2. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, Guguen-Guillouzo C, Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006; 34: 75-83.
3. Arefayene M, Skaar TC, Zhao X, Rae JM, Tanus-Santos JE, Brinkmann U, Brehm I, Salat U, Nguyen A, Desta Z, Flockhart DA. Sequence diversity and functional characterization of the 5 '-regulatory region of human CYP2C19. Pharmacogenetics 2003; 13: 199-206.
4. Auerbach SS, Stoner MA, Su S, Omiecinski CJ. Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3). Mol Pharmacol 2005; 68: 1239-1253.
5. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, Grompe M. Robust expansion of human hepatocytes in Fah -/-/Rag2 -/- /Il2rg -/- mice. Nat Biotechnol 2007; 25: 903-910.
6. Backlund M, Ingelman-Sundberg M. Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. Cell Signal 2005; 17: 39-48.
7. Beischlag TV, Wang S, Rose DW, Torchia J, Reisz-Porszasz S, Muhammad K, Nelson WE, Probst MR, Rosenfeld MG, Hankinson O. Recruitment of the NCoA/SRC-1/ p160 family of transcriptional coactivators by the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator complex. Mol Cell Biol 2002; 22: 4319-4333.
8. Bell AW, Michalopoulos GK. Phenobarbital regulates nuclear expression of HNF-4alpha in mouse and rat hepatocytes independent of CAR and PXR. Hepatology 2006; 44: 186-194.
9. Bjornsson T, Callaghan J, Einolf H, Fischer V, Gan L, Grimm S, Kao J, King S, Miwa G, Ni L, Kumar G, McLeod J, Obach R, Roberts S, Roe A, Shah A, Snikeris F, Sullivan J, Tweedie D, Vega J, Walsh J, Wrighton S. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-832.
10. Bonzo J, Chen S, Galijatovic A, Tukey R. Arsenite inhibition of CYP1A1 induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin is independent of cell cycle arrest. Mol Pharmacol 2005; 67: 1247-1256.
11. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Gripon P, Kremsdorf D, Guguen-Guillouzo C, Corlu A. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007; 45: 957-967.
12. Chang TK, Waxman DJ. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 2006; 38: 51-73.
13. Conney AH. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967; 19: 317-366.
14. Dickins M. Induction of cytochromes P450. Curr Top Med Chem 2004; 4: 1745-1766.
15. Dimaraki EV, Jaffe CA. Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab 2003; 88: 3113-3116.
16. Ek M, Soderdahl T, Kuppers-Munther B, Edsbagge J, Andersson TB, Bjorquist P, Cotgreave I, Jernstrom B, Ingelman-Sundberg M, Johansson I. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 2007; 74: 496-503.
17. Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, Iyer M, Kholodovych V, Ai N, Welsh WJ, Sinz M, Swaan PW, Patel R, Bachmann K. Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 2007; 72: 592-603.
18. El-Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001; 29: 1499-1504.
19. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007; 320: 72-80.
20. FDA. Guidance for Industry on Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling.
21. FDA. Guidance for Industry-Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro. Food and Drug Administration Publication, 2006.
22. Gao YD, Olson SH, Balkovec JM, Zhu Y, Royo I, Yabut J, Evers R, Tan EY, Tang W, Hartley DP, Mosley RT. Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica 2007; 37: 124-138.
23. Gomez-Lechon MJ, Donato T, Jover R, Rodriguez C, Ponsoda X, Glaise D, Castell JV, Guguen-Guillouzo C. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur J Biochem 2001; 268: 1448-1459.
24. Gonzalez F. Cyp2e1. Drug Metab Dispos 2007; 35: 1-8.
25. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999; 56: 1329-1339.
26. Guengerich FP, Shimada T, Iwasaki M, Butler MA, Kadlubar FF. Activation of carcinogens by human liver cytochromes P-450. Basic Life Sci 1990; 53: 381-396.
27. Gupta A, Mugundu G, Desai PB, Thummel KE, Unadkat JD. Intestinal human colon adenocarcinoma cell line, LS180, is an excellent model to study PXR-but not CAR-mediated CYP3A4 and MDR1 induction: studies with anti-HIV protease inhibitors. Drug Metab Dispos 2008; 36 ( 6): 1172-1180.
28. Hamilton GA, Jolley SL, Gilbert D, Coon DJ, Barros S, LeCluyse EL. Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res 2001; 306: 85-99.
29. Handschin C, Podvinec M, Meyer UA. In silico approaches, and in vitro and in vivo experiments to predict induction of drug metabolism. Drug News Perspect 2003; 16: 423-434.
30. Hariparsad N, Carr BA, Evers R, Chu X. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 2008; 36: 1046-1055.
31. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev 2007; 33: 369-380.
32. Harris RZ, Inglis AM, Miller AK, Thompson KA, Finnerty D, Patterson S, Jorkasky DK, Freed MI. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol 1999; 39: 1189-1194.
33. Hay DC, Zhao D, Ross A, Mandalam R, Lebkowski J, Cui W. Direct differentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. Cloning Stem Cells 2007; 9: 51-62.
34. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-457.
35. Herrera MB, Bruno S, Buttiglieri S, Tetta C, Gatti S, Deregibus MC, Bussolati B, Camussi G. Isolation and characterization of a stem cell population from adult human liver. Stem Cells 2006; 24: 2840-2850.
36. Hewitt NJ, de Kanter R, LeCluyse E. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry-do they comply with FDA recommendations? Chem Biol Interact 2007; 168: 51-65.
37. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008; 48: 662-670.
38. Josephy P. Molecular Toxicology, Josephy P, Mannervik B, editors. New York: Oxford University Press, 2005.
39. Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 2001; 33: 668-675.
40. Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 2007; 22: 287-298.
41. Kanebratt KP, Andersson TB. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 2008a; 36: 1444-1452.
42. Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 2008b; 36: 137-145.
43. Katoh M, Watanabe M, Tabata T, Sato Y, Nakajima M, Nishimura M, Naito S, Tateno C, Iwasaki K, Yoshizato K, Yokoi T. In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. Xenobiotica 2005; 35: 863-875.
44. Kawana K, Ikuta T, Kobayashi Y, Gotoh O, Takeda K, Kawajiri K. Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol Pharmacol 2003; 63: 524-531.
45. Kazemnejad S, Allameh A, Seoleimani M, Gharehbaghian A, Mohammadi Y, Amirizadeh N, Esmaeili S. Functional hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel 3-dimensional biocompatible nanofibrous scaffold. Int J Artif Organs 2008; 31: 500-507.
46. Kim S, Pray D, Zheng M, Morgan D, Pizzano J, Zoeckler M, Chimalakonda A, Sinz M. Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: Extrapolation to human P450 induction potential. Drug Metab Lett 2008; 2: 169-175.
47. Kodama S, Koike C, Negishi M, Yamamoto Y. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol 2004; 24: 7931-7940.
48. Kohn M, Portier C. Effects of the mechanism of receptor-mediated gene expression on the shape of the dose-response. Risk Analysis 1993; 13: 565-572.
49. Koop DR, Tierney DJ. Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. Bioessays 1990; 12: 429-435.
50. Kostrubsky VE, Strom SC, Hanson J, Urda E, Rose K, Burliegh J, Zocharski P, Cai H, Sinclair JF, Sahi J. Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 2003; 76: 220-228.
51. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair JF. Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch Biochem Biophys 1995; 322: 516-520.
52. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 2006; 28: 109-117.
53. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001; 13: 343-368.
54. LeCluyse EL, Audus KL, Hochman JH. Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol 1994; 266 :C 1764-1774.
55. LeCluyse E, Bullock P, Madan A, Carroll K, Parkinson A. Influence of extracellular matrix overlay and medium formulation on the induction of cytochrome P-450 2B enzymes in primary cultures of rat hepatocytes. Drug Metab Dispos 1999; 27: 909-915.
56. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, Parkinson A. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2000; 14: 177-188.
57. LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, Richert L. Isolation and culture of primary human hepatocytes. Methods Mol Biol 2005; 290: 207-229.
58. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-1023.
59. Lemaire G, Benod C, Nahoum V, Pillon A, Boussioux AM, Guichou JF, Subra G, Pascussi JM, Bourguet W, Chavanieu A, Balaguer P. Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to " in vivo " biological activity. Mol Pharmacol 2007; 72: 572-581.
60. Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 1999; 121: 17-35.
61. Lim YP, Huang JD. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet 2008; 23: 14-21.
62. Lin JH. CYP Induction-Mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006; 23: 1089-1116.
63. Liu FJ, Song X, Yang D, Deng R, Yan B. The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha. Biochem J 2008; 409: 243-250.
64. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P, Jr., Koch P, Antonian L, Wagner G, Yu L, Parkinson A. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003; 31: 421-431.
65. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000; 68: 356-366.
66. Medina-Diaz IM, Elizondo G. Transcriptional induction of CYP3A4 by o,p '-DDT in HepG2 cells. Toxicol Lett 2005; 157: 41-47.
67. Mills JB, Rose KA, Sadagopan N, Sahi J, de Morais SM. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004; 309: 303-309.
68. Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 2000; 153: 1-10.
69. Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, Moore JT. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 2002; 16: 977-986.
70. 2+. J Biol Chem 1985; 260: 13035-13040.
71. Moreau A, Maurel P, Vilarem MJ, Pascussi JM. Constitutive androstane receptor-vitamin D receptor crosstalk: consequence on CYP24 gene expression. Biochem Biophys Res Commun 2007; 360: 76-82.
72. Nakata K, Tanaka Y, Nakano T, Adachi T, Tanaka H, Kaminuma T, Ishikawa T. Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems. Drug Metab Pharmacokinet 2006; 21: 437-457.
73. Nishimura M, Imai T, Morioka Y, Kuribayashi S, Kamataki T, Naito S. Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. Drug Metab Pharmacokinet 2004; 19: 422-429.
74. Nishimura M, Yokoi T, Tateno C, Kataoka M, Takahashi E, Horie T, Yoshizato K, Naito S. Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 2005; 20: 121-126.
75. Novak RF, Woodcroft KJ. The alcohol-inducible form of cytochrome P450 (CYP 2E1): role in toxicology and regulation of expression. Arch Pharm Res 2000; 23: 267-282.
76. O' Connor JE, Martinez A, Castell JV, Gomez-Lechon MJ. Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research. Cytometry A 2005; 63: 48-58.
77. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, Fraenkel E, Bell GI, Young RA. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004; 303: 1378-1381.
78. Onica T, Nichols K, Larin M, Ng L, Maslen A, Dvorak Z, Pascussi JM, Vilarem MJ, Maurel P, Kirby GM. Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Mol Pharmacol 2008; 73: 451-460.
79. Pacussi JM, Vilarem MJ. Drug-induced osteomalacia: possible role of PXR, a receptor involved in detoxification. Med Sci (Paris) 2005; 21: 582-583.
80. Parkinson A. Biotransformation of xenobiotics. In: Toxicology: The Basic Science of Poisons. ( Klassen C ed), New York: McGraw-Hill, 2001, pp. 133-224.
81. Qatanani M, Moore DD. CAR, the continuously advancing receptor, in drug metabolism and disease. Curr Drug Metab 2005; 6: 329-339.
82. Raucy JL, Lasker J, Ozaki K, Zoleta V. Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci 2004; 79: 233-241.
83. Reinach B, de Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 1999; 121: 37-48.
84. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, de Morais SM. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 2006; 34: 1742-1748.
85. Roymans D, Annaert P, Van Houdt J, Weygers A, Noukens J, Sensenhauser C, Silva J, Van Looveren C, Hendrickx J, Mannens G, Meuldermans W. Expression and induction potential of cytochromes p450 in human cryopreserved hepatocytes. Drug Metab Dispos 2005; 33: 1004-1016.
86. Ruhnke M, Nussler AK, Ungefroren H, Hengstler JG, Kremer B, Hoeckh W, Gottwald T, Heeckt P, Fandrich F. Human monocyte-derived neohepatocytes: a promising alternative to primary human hepatocytes for autologous cell therapy. Transplantation 2005; 79: 1097-1103
87. Sahi J, Hamilton G, Sinz M, Barros S, Huang SM, Lesko LJ, LeCluyse EL. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 2000; 30: 273-284.
88. Sahi J, Stern RH, Milad MA, Rose KA, Gibson G, Zheng X, Stilgenbauer L, Sadagopan N, Jolley S, Gilbert D, LeCluyse EL. Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo. Drug Metab Dispos 2004; 32: 1370-1376.
89. Sahi J, Sinz MW, Campbell S, Mireles R, Zheng X, Rose KA, Raeissi S, Hashim MF, Ye Y, de Morais SM, Black C, Tugnait M, Keller LH. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem Biol Interact 2006; 159: 156-168.
90. Sahi J, Shord S, Ferguson S, LeCluyse E. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2009; 23 ( 1): 43-58.
91. Schehrer L, Regan JD, Westendorf J. UDS induction by an array of standard carcinogens in human and rodent hepatocytes: effect of cryopreservation. Toxicology 2000; 147: 177-191.
92. Schmiedlin-Ren P, Thummel K, Fisher J, Paine M, Watkins P. Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab Dispos 2001; 29: 1446-1453.
93. Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002; 109: 1291-1302.
94. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, Rodrigues AD. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006; 7: 375-388.
95. Sinz M, Kim S, Ferguson S, LeCluyse E. Evaluating and predicting human cytochrome P450 enzyme induction. In: Nassar A, editor. Drug Metabolism in Pharmaceuticals: Concepts and Application. New York: John Wiley & Sons, 2008a.
96. Sinz M, Wallace G, Sahi J. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 2008b; 10: 391-400.
97. Smith CM, Faucette SR, Wang H, Lecluyse EL. Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers. J Biochem Mol Toxicol 2005; 19: 96-108.
98. Smith DA, Dickins M, Fahmi OA, Iwasaki K, Lee C, Obach RS, Padbury G, De Morais SM, Ripp SL, Stevens J, Voorman R, Youdim K. The time to move cytochrome P450 induction into mainstream pharmacology is long overdue. Drug Metab Dispos 2007; 35: 697-698.
99. Squires EJ, Sueyoshi T, Negishi M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem 2004; 279: 49307-49314.
100. Stjernschantz E, Vermeulen NP, Oostenbrink C. Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450. Expert Opin Drug Metab Toxicol 2008; 4: 513-527.
101. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999; 274: 6043-6046.
102. Swales K, Kakizaki S, Yamamoto Y, Inoue K, Kobayashi K, Negishi M. Novel CAR-mediated mechanism for synergistic activation of two distinct elements within the human cytochrome P450 2B6 gene in HepG2 cells. J Biol Chem 2005; 280: 3458-3466.
103. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, Yoshizato K. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-912.
104. Terry TL, Gallin WJ. Effects of fetal calf serum and disruption of cadherin function on the formation of bile canaliculi between hepatocytes. Exp Cell Res 1994; 214: 642-653.
105. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005; 94: 1169-1186.
106. Wang H, LeCluyse E. Role of orphan nuclear receptors in the regulation of drug metabolizing enzymes. Clin Pharmacokinet 2003; 42: 1331-1357.
107. Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E. Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 2004; 279: 29295-29301.
108. Wang H, Huang H, Li H, Teotico DG, Sinz M, Baker SD, Staudinger J, Kalpana G, Redinbo MR, Mani S. Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res 2007; 13: 2488-2495.
109. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, Redinbo MR. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001; 292: 2329-2333.
110. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line HEPG2 with regard to their biotransformation properties. Drug Metab Dispos 2003; 31: 1035-1042.
111. Xiao L, Cui X, Madison V, White RE, Cheng KC. Insights from a three-dimensional model into ligand binding to constitutive active receptor. Drug Metab Dispos 2002; 30: 951-956.
112. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS, Evans RM. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000; 406: 435-439.
113. Yoshitsugu H, Nishimura M, Tateno C, Kataoka M, Takahashi E, Soeno Y, Yoshizato K, Yokoi T, Naito S. Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 2006; 21: 465-474.
114. Yueh MF, Kawahara M, Raucy J. Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol In Vitro 2005; 19: 275-287.
115. Zhou C, Assem M, Tay J, Watkins P, Blumberg B, Schuetz E, Thummel K. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006; 116: 1703-1712.
116. Zhu Z, Kim S, Chen T, Lin JH, Bell A, Bryson J, Dubaquie Y, Yan N, Yanchunas J, Xie D, Stoffel R, Sinz M, Dickinson K. Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 2004; 9: 533-540.